Rallybio (RLYB) Competitors $0.75 -0.02 (-2.09%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$0.78 +0.03 (+3.71%) As of 02/21/2025 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends RLYB vs. TSVT, BDTX, IVA, CABA, NVCT, RENB, CRBU, CRBP, MIST, and VTYXShould you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include 2seventy bio (TSVT), Black Diamond Therapeutics (BDTX), Inventiva (IVA), Cabaletta Bio (CABA), Nuvectis Pharma (NVCT), Renovaro (RENB), Caribou Biosciences (CRBU), Corbus Pharmaceuticals (CRBP), Milestone Pharmaceuticals (MIST), and Ventyx Biosciences (VTYX). These companies are all part of the "pharmaceutical products" industry. Rallybio vs. 2seventy bio Black Diamond Therapeutics Inventiva Cabaletta Bio Nuvectis Pharma Renovaro Caribou Biosciences Corbus Pharmaceuticals Milestone Pharmaceuticals Ventyx Biosciences 2seventy bio (NASDAQ:TSVT) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, dividends, risk, institutional ownership, valuation, analyst recommendations, earnings, community ranking and media sentiment. Does the media favor TSVT or RLYB? In the previous week, 2seventy bio had 4 more articles in the media than Rallybio. MarketBeat recorded 4 mentions for 2seventy bio and 0 mentions for Rallybio. 2seventy bio's average media sentiment score of 0.15 beat Rallybio's score of 0.00 indicating that 2seventy bio is being referred to more favorably in the media. Company Overall Sentiment 2seventy bio Neutral Rallybio Neutral Do insiders and institutionals hold more shares of TSVT or RLYB? 93.9% of 2seventy bio shares are owned by institutional investors. Comparatively, 90.3% of Rallybio shares are owned by institutional investors. 7.2% of 2seventy bio shares are owned by company insiders. Comparatively, 7.4% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is TSVT or RLYB more profitable? Rallybio has a net margin of 0.00% compared to 2seventy bio's net margin of -207.25%. 2seventy bio's return on equity of -53.65% beat Rallybio's return on equity.Company Net Margins Return on Equity Return on Assets 2seventy bio-207.25% -53.65% -23.67% Rallybio N/A -77.39%-69.33% Which has stronger valuation and earnings, TSVT or RLYB? Rallybio has lower revenue, but higher earnings than 2seventy bio. 2seventy bio is trading at a lower price-to-earnings ratio than Rallybio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio2seventy bio$100.39M1.34-$217.57M-$1.86-1.40RallybioN/AN/A-$74.56M-$1.60-0.47 Do analysts rate TSVT or RLYB? 2seventy bio currently has a consensus target price of $7.20, indicating a potential upside of 175.86%. Rallybio has a consensus target price of $9.75, indicating a potential upside of 1,193.10%. Given Rallybio's stronger consensus rating and higher possible upside, analysts clearly believe Rallybio is more favorable than 2seventy bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 2seventy bio 1 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.50Rallybio 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Which has more risk & volatility, TSVT or RLYB? 2seventy bio has a beta of 1.74, suggesting that its share price is 74% more volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.49, suggesting that its share price is 249% less volatile than the S&P 500. Does the MarketBeat Community prefer TSVT or RLYB? Rallybio received 18 more outperform votes than 2seventy bio when rated by MarketBeat users. Likewise, 78.18% of users gave Rallybio an outperform vote while only 52.08% of users gave 2seventy bio an outperform vote. CompanyUnderperformOutperform2seventy bioOutperform Votes2552.08% Underperform Votes2347.92% RallybioOutperform Votes4378.18% Underperform Votes1221.82% SummaryRallybio beats 2seventy bio on 10 of the 18 factors compared between the two stocks. Get Rallybio News Delivered to You Automatically Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLYB vs. The Competition Export to ExcelMetricRallybioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.95M$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-0.475.4725.4719.00Price / SalesN/A306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book0.276.717.644.62Net Income-$74.56M$138.33M$3.18B$245.85M7 Day Performance0.07%-2.61%-1.99%-2.68%1 Month Performance-13.55%-2.32%-0.42%-2.19%1 Year Performance-58.80%-5.31%16.51%12.84% Rallybio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLYBRallybio2.45 of 5 stars$0.75-2.1%$9.75+1,193.1%-58.1%$31.95MN/A-0.4740TSVT2seventy bio2.1813 of 5 stars$2.45+6.5%$7.20+193.9%-53.2%$126.40M$100.39M-1.32440Analyst ForecastNews CoverageBDTXBlack Diamond Therapeutics3.3805 of 5 stars$2.23-9.3%$15.50+595.1%-53.7%$126.17MN/A-1.6890Short Interest ↓Positive NewsIVAInventiva2.0097 of 5 stars$2.37-2.4%$13.25+458.8%-13.1%$124.43M$18.91M0.00100Analyst ForecastNews CoverageGap UpCABACabaletta Bio2.2422 of 5 stars$2.53-4.5%$22.71+797.8%-90.7%$123.67MN/A-1.1850Analyst ForecastNVCTNuvectis Pharma2.4047 of 5 stars$6.33-5.7%$21.00+231.8%+7.2%$122.30MN/A-5.468RENBRenovaro0.763 of 5 stars$0.75+7.5%N/A-61.1%$119.59MN/A-0.7820Earnings ReportNews CoverageGap UpCRBUCaribou Biosciences3.1342 of 5 stars$1.32-2.2%$10.33+682.8%-80.8%$119.53M$34.48M-0.80100Gap UpCRBPCorbus Pharmaceuticals4.043 of 5 stars$9.78-3.6%$61.38+527.6%-69.9%$119.11MN/A-2.0940Analyst ForecastGap DownMISTMilestone Pharmaceuticals2.8119 of 5 stars$2.23+3.7%$13.00+483.0%+29.1%$118.93M$1M-2.7530VTYXVentyx Biosciences3.1131 of 5 stars$1.67-3.5%$10.00+498.8%-68.1%$118.09MN/A-0.7130Upcoming Earnings Related Companies and Tools Related Companies 2seventy bio Alternatives Black Diamond Therapeutics Alternatives Inventiva Alternatives Cabaletta Bio Alternatives Nuvectis Pharma Alternatives Renovaro Alternatives Caribou Biosciences Alternatives Corbus Pharmaceuticals Alternatives Milestone Pharmaceuticals Alternatives Ventyx Biosciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:RLYB) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredWe recommended Palantir in 2021, now we’re recommending this...I believe it could offer you a MAJOR boost to your retirement. And it pays huge dividends to give you a nic...Behind the Markets | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLYB Stock Alerts